tbuckley/cabot-search huggingface dataset:
P1.16-04 Outcomes of Patients &lt;70 or ≥70 Years of Age in PACIFIC
Authors: M. Socinski, M. Özgüroğlu, A. Villegas, D. Daniel, D. Vicente, S. Murakami, R. Hui, J. Gray, K. Park, M. Vincent, F. Perrone, L. Poole, C. Wadsworth, P. Dennis, S. Antonia
Journal: Journal of Thoracic Oncology (2018)
Effect of mandibular advancement therapy on inflammatory and metabolic biomarkers in patients with severe obstructive sleep apnoea: a randomised controlled trial
Authors: Sylvain Recoquillon, Jean-Louis Pépin, Bruno Vielle, Ramaroson Andriantsitohaina, Vanessa Bironneau, Frédérique Chouet-Girard, Bernard Fleury, François Goupil, Sandrine Launois, M Carmen Martinez, Nicole Meslier, Xuan-Lan Nguyen, Audrey Paris, Pascaline Priou, Renaud Tamisier, Wojciech Trzepizur, Frédéric Gagnadoux
Journal: Thorax (2018)

Systemic inflammation and metabolic disorders are among the mechanisms linking obstructive sleep apnoea (OSA) and cardiovascular disease (CVD). In 109 patients with severe OSA and no overt CVD, biomarkers of inflammation (C reactive protein, interleukin-6, tumour necrosis factor-α and its receptors, adiponectin, leptin and P-selectin), glucose and lipid metabolism, and N-terminal pro-brain natriuretic peptide, were measured before and after 2 months of treatment with a mandibular advancement device (MAD) (n=55) or a sham device (n=54). MAD reduced the Apnoea-Hypopnoea Index (p<0.001) but had no effect on circulating biomarkers compared with the sham device, despite high treatment adherence (6.6 hour/night). TRIAL REGISTRATION NUMBER: NCT01426607.
MA04.03 Immunotherapy for Non-Small Cell Lung Cancers (NSCLC) with Oncogenic Driver Mutations: New Results from the Global IMMUNOTARGET Registry
Authors: O. Gautschi, A. Drilon, J. Milia, A. Lusque, L. Mhanna, B. Li, J. Sabari, A. Cortot, B. Besse, L. Mezquita, B. Solomon, A. Thai, S. Couraud, R. Veillon, C. Mascaux, F. Barlesi, M. Van Den Heuvel, R. Schouten, H. Wakelee, A. Mah, D.R. Camidge, T. Ng, N. Peled, Y. Lilach, S. Popat, S. Ou, V. Zhu, V. Velcheti, A. Curioni Fontecedro, D. Akhoundova, M. Früh, G. Zalcman, V. Gounant, S. Novello, P. Bironzo, E. Felip, A. Martinez-Marti, D. Moro-Sibilot, R. Rosell, N. Karachaliou, M. Schuler, M. Wiesweg, J. Diebold, J. Mazieres
Journal: Journal of Thoracic Oncology (2018)
Metformin for Treatment of Fragile X Syndrome and Other Neurological Disorders
Authors: Ilse Gantois, Jelena Popic, Arkady Khoutorsky, Nahum Sonenberg
Journal: Annual Review of Medicine (2018)

Fragile X syndrome (FXS) is the most frequent inherited form of intellectual disability and autism spectrum disorder. Loss of the fragile X mental retardation protein, FMRP, engenders molecular, behavioral, and cognitive deficits in FXS patients. Experiments using different animal models advanced our knowledge of the pathophysiology of FXS and led to the discovery of many targets for drug treatments. In this review, we discuss the potential of metformin, an antidiabetic drug approved by the US Food and Drug Administration, to correct core symptoms of FXS and other neurological disorders in humans. We summarize its mechanisms of action in different animal and cellular models and human diseases.
Development and validation of neuroendocrine tumor marker panel in small biopsies using multiplexed mass spectrometry
Authors: S. Thyparambil, E. An, S. Sellappan, E.R. Wertheimer, S. Landolfi, J. Capdevila, F. Cecchi, P.G. Nuciforo, R. Heaton, T. Hembrough
Journal: Annals of Oncology (2018)
A phase I study to determine the maximum tolerated dose of trifluridine/tipiracil and oxaliplatin in patients with refractory metastatic colorectal cancer: LUPIN study
Authors: M. Suenaga, T. Wakatsuki, M. Ogura, T. Ichimura, E. Shinozaki, I. Nakayama, H. Osumi, Y. Ota, K. Chin, T. Mashima, H. Seimiya, D. Takahari, K. Yamaguchi
Journal: Annals of Oncology (2018)
Assessment of quality of life in patients with metastatic melanoma in real clinical practice in France
Authors: M. Kandel, C. Allayous, S. Dalle, L. Mortier, S. Dalac Rat, C. Dutriaux, M.-T. Leccia, B. Guillot, P. Saiag, J.-P. Lacour, D. Legoupil, F. Brunet-Possenti, B. Dreno, A. Ballon, A. Bardet, S. Michiels, C. Lebbe, I. Borget
Journal: Annals of Oncology (2018)
The cognitive-emotional brain: Opportunitvnies and challenges for understanding neuropsychiatric disorders
Authors: Alexander J. Shackman, Andrew S. Fox, David A. Seminowicz
Journal: Behavioral and Brain Sciences (2015)

Abstract Many of the most common neuropsychiatric disorders are marked by prominent disturbances of cognition and emotion. Characterizing the complex neural circuitry underlying the interplay of cognition and emotion is critically important, not just for clarifying the nature of the mind, but also for discovering the root causes of a broad spectrum of debilitating neuropsychiatric disorders, including anxiety, schizophrenia, and chronic pain.
P2.03-28 Whole Exome Sequencing to Discover Lung Tumor Predisposition in Women with Previous Breast Cancer
Authors: F. Grossi, C. Genova, S. Bonfiglio, D. Cittaro, I. Vanni, M. Mora, S. Boccardo, M.G. Dal Bello, E. Rijavec, C. Sini, A. Alama, G. Barletta, F. Biello, G. Rossi, M. Tagliamento, G. Burrafato, A. Ballestrero, S. Coco
Journal: Journal of Thoracic Oncology (2018)
The NCI Transcriptional Pharmacodynamics Workbench: A Tool to Examine Dynamic Expression Profiling of Therapeutic Response in the NCI-60 Cell Line Panel
Authors: Anne Monks, Yingdong Zhao, Curtis Hose, Hossein Hamed, Julia Krushkal, Jianwen Fang, Dmitriy Sonkin, Alida Palmisano, Eric C. Polley, Laura K. Fogli, Mariam M. Konaté, Sarah B. Miller, Melanie A. Simpson, Andrea Regier Voth, Ming-Chung Li, Erik Harris, Xiaolin Wu, John W. Connelly, Annamaria Rapisarda, Beverly A. Teicher, Richard Simon, James H. Doroshow
Journal: Cancer Research (2018)

Abstract The intracellular effects and overall efficacies of anticancer therapies can vary significantly by tumor type. To identify patterns of drug-induced gene modulation that occur in different cancer cell types, we measured gene-expression changes across the NCI-60 cell line panel after exposure to 15 anticancer agents. The results were integrated into a combined database and set of interactive analysis tools, designated the NCI Transcriptional Pharmacodynamics Workbench (NCI TPW), that allows exploration of gene-expression modulation by molecular pathway, drug target, and association with drug sensitivity. We identified common transcriptional responses across agents and cell types and uncovered gene-expression changes associated with drug sensitivity. We also demonstrated the value of this tool for investigating clinically relevant molecular hypotheses and identifying candidate biomarkers of drug activity. The NCI TPW, publicly available at https://tpwb.nci.nih.gov, provides a comprehensive resource to facilitate understanding of tumor cell characteristics that define sensitivity to commonly used anticancer drugs. Significance: The NCI Transcriptional Pharmacodynamics Workbench represents the most extensive compilation to date of directly measured longitudinal transcriptional responses to anticancer agents across a thoroughly characterized ensemble of cancer cell lines.
Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM)
Authors: D. Peereboom, L.B. Nabors, P. Kumthekar, M. Badruddoja, K. Fink, F. Lieberman, S. Phuphanich, E. Dunbar, T. Walbert, D. Schiff, D.D. Tran, L.S. Ashby, N. Butowski, F. Iwamoto, R. Lindsay, J. Bullington, M. Schulder, J. Sherman, C. Brooks, D. Reardon
Journal: Annals of Oncology (2018)
Maintenance chemotherapy versus follow-up after carboplatin and weekly paclitaxel doublet chemotherapy in elderly patients with advanced non-small cell lung cancer (NSCLC): IFCT-1201 MODEL randomised phase III trial
Authors: E. Quoix, C. Audigier Valette, A. Lavolé, O. Molinier, V. Westeel, F. Barlesi, J. Le Treut, E. Pichon, J. Dauba, J. Otto, P. Dumont, L. Moreau, J. Madelaine, J. Margery, D. Debieuvre, P.A. Renault, A. Langlais, F. Morin, D. Moro-Sibilot, P.-J. Souquet
Journal: Annals of Oncology (2018)
P1.13-19 Treatment Cessation for Improved Detection of EGFR-Mutated Circulating Tumor DNA in Advanced Non-Small Cell Lung Cancer (aNSCLC)
Authors: S. Tabchi, S. Forte, R. Alameddine, A. Khazzaka, M. Florescu, E. Kassouf, X. Weng, M. Tehfe, N. Blais
Journal: Journal of Thoracic Oncology (2018)
P1.16-07 Cost-Effectiveness of Pembrolizumab as 1st Line Treatment for Metastatic NSCLC Patients with High PD-L1 Expression in Singapore
Authors: W.L. Tan, M. Huang, S. Chandwani, T. Hsu, S.C. Tan, D. Tan
Journal: Journal of Thoracic Oncology (2018)
P1.16-06 Expanded Efficacy and Safety Analysis of PACIFIC Based on a PD-L1 Cutpoint of 25%
Authors: A. Spira, D. Planchard, B.C. Cho, M. Özgüroğlu, D. Daniel, A. Villegas, D. Vicente, R. Hui, S. Murakami, L. Paz-Ares, A. Boothman, L. Poole, C. Wadsworth, P. Dennis, S. Antonia
Journal: Journal of Thoracic Oncology (2018)
In renovascular hypertension, TNF-α type-1 receptors in the area postrema mediate increases in cardiac and renal sympathetic nerve activity and blood pressure
Authors: Willian S Korim, Khalid Elsaafien, Jeremy R Basser, Anthony Setiadi, Clive N May, Song T Yao
Journal: Cardiovascular Research (2018)

Neuroinflammation is a common feature in renovascular, obesity-related, and angiotensin II mediated hypertension. There is evidence that increased release of the pro-inflammatory cytokine tumour necrosis factor-α (TNF-α) contributes to the development of the hypertension, but the underlying neural mechanisms are unclear. Here, we investigated whether TNF-α stimulates neurons in the area postrema (AP), a circumventricular organ, to elicit sympathetic excitation, and increases in blood pressure (BP).In rats with renovascular hypertension, AP neurons that expressed TNF-α type-1 receptor (TNFR1) remained constantly activated (expressed c-Fos) and injection of TNFR1 neutralizing antibody into the AP returned BP (systolic: ∼151 mmHg) to normotensive levels (systolic: ∼108 mmHg). Nanoinjection of TNF-α (100 pg/50 nL) into the AP of anaesthetized normotensive rats increased BP (∼16 mmHg) and sympathetic nerve activity, predominantly to the heart (∼53%), but also to the kidneys (∼35%). These responses were abolished by prior injection of a TNFR1 neutralizing antibody (1 ng/50 nL) within the same site. TNFR1 were expressed in the somata of neurons activated by TNF-α that were retrogradely labelled from the rostral ventrolateral medulla (RVLM).These findings indicate that in renovascular hypertension, blocking TNFR1 receptors in the AP significantly reduces BP, while activation of TNFR1 expressing neurons in the AP by TNF-α increases BP in normotensive rats. This is mediated, in part, by projections to the RVLM and an increase in both cardiac and renal sympathetic nerve activity. These findings support the notion that proinflammatory cytokines and neuroinflammation are important pathological mechanisms in the development and maintenance of hypertension.
P1.16-42 Indocyanine Green Intersegmental Visualization During Fluorescence Imaging of Thoracoscopic Anatomic Segmentectomy: A Novel Approach
Authors: T. Matsui, H. Kuroda, Y. Sugita, S. Koyama, K. Nakanishi, T. Arimura, T. Mizuno, N. Sakakura, Y. Sakao
Journal: Journal of Thoracic Oncology (2018)
P2.04-01 Associations Histological Subtype of Lung Adenocarcinoma and Programmed Death Ligand 1 (PD-L1) Expression in Tumor Cells.
Authors: G. Cruz-Rico, X. Popa Navarro, A. Avilés-Salas, K.Y. Flores-Vélez, A. Cardona, L. Ramírez-Tirado, E. Vergara, F. Barron, L.A. Cabrera-Miranda, O. Arrieta
Journal: Journal of Thoracic Oncology (2018)
P2.09-21 Women with Synchronous or Metachronous Lung and Ovarian Cancers: A Multi-Institutional Report
Authors: A. Mariniello, E. Ghisoni, L. Righi, A. Catino, R. Chiari, A. Del Conte, F. Barbieri, F.L. Cecere, A. Gelibter, M. Giaj Levra, H. Soto Parra, C. Zichi, G. Valabrega, S. Novello
Journal: Journal of Thoracic Oncology (2018)
Serial circulating tumor DNA analysis for detection of residual disease, assessment of adjuvant therapy efficacy and for early recurrence detection in colorectal cancer
Authors: T. Reinert, T.V. Henriksen, M.H. Rasmussen, H. Sethi, R. Salari, S. Shchegrova, R. Swenerton, H.-T. Wu, S. Sharma, E. Christensen, P. Natarajan, S. Dashner, T. Tin, A. Olson, H. Pawar, B. Zimmermann, L.H. Iversen, M.R. Madsen, J. Lin, C.L. Andersen
Journal: Annals of Oncology (2018)
LungBEAM: A prospective multicenter trial to monitor EGFR mutations using BEAMing technology in stage IV NSCLC patients
Authors: P. Garrido Lopez, E. Felip, L. Paz-Ares, M. Majem, T. Moran, J.L. Gonzalez-Larriba, J. Bosch Barrera, J.M. Trigo Perez, M.R. Garcia Campelo, J.M. Sanchez Torres, D. Isla, N. Vinolas Segarra, C. Camps, A. Insa Molla, O.J. Juan Vidal, B. Massutí, A. Paredes Lario, A. Artal-Cortes, M. Lopez-Brea Piqueras, J. Palacios Calvo
Journal: Annals of Oncology (2018)
P2.01-132 Comparison Molecular Profiles in NSCLC by Using Different NGS Platforms and Different Variant Frequency Cutoff
Authors: S. Lukrak, P. Incharoen, S. Detarkom, S. Techasurungkul, N. Trachu, N. Iemwimangsa, P. Janchompoo, W. Chantratita, T. Reungwetwattana
Journal: Journal of Thoracic Oncology (2018)
MA05.06 Locally Advanced Lung Cancer Radiotherapy in Deep Inspiration Breath Hold: Dosimetric Benefits from a Prospective Trial
Authors: M. Josipovic, M. Aznar, J. Rydhög, J. Thomsen, S. Damkjaer, L. Nygård, M. Pøhl, S. Langer, L. Specht, G. Persson
Journal: Journal of Thoracic Oncology (2018)
OA02.05 CK-101 (RX518), a Third Generation Mutant-Selective Inhibitor of EGFR in NSCLC: Results of an Ongoing Phase I/II Trial
Authors: M. Johnson, J. Karlix, H. Burris, S. Jones, D. Harris, K. O'Byrne, V. Sriuranpong, C. Charoentum, N. Prasongsook, W. Jitpewngam, K. Wirasorn, J. Wang, S. Waqar, J. Oliviero, L. Gorelik, X. Qian
Journal: Journal of Thoracic Oncology (2018)
Monitoring quality of life in Dutch women with breast cancer: The Care Notebook study
Authors: R.T. Lugtenberg, M.J. Fischer, F. de Jongh, K. Inoue, A. Matsuda, S.R.S. Ramai, J.W. Nortier, H. Putter, K. Yamaoka, K. Kubota, K. Kobayashi, A.A. Kaptein, J.R. Kroep
Journal: Annals of Oncology (2018)
P1.05-13 The Demonstration of the Possibility of the Pleura Cryo Biopsy – A Preliminary Report
Authors: J. Pierog, B. Kubisa, J. Wójcik, M. Wojtyś, M. Bielewicz, B. Maciąg, N. Wójcik, T. Grodzki
Journal: Journal of Thoracic Oncology (2018)
OA08.06 Tumour Suppressor MicroRNAs Modulate Drug Resistance by Targeting Anti-Apoptotic Pathways in Malignant Pleural Mesothelioma (MPM)
Authors: M. Williams, Y.Y. Cheng, M. Phimmachanh, P. Winata, G. Reid
Journal: Journal of Thoracic Oncology (2018)
P2.16-16 SABRTOOTH: A Fasibility Study of SABR Versus Surgery in Patients with Peripheral Stage I NSCLC Considered to be at Higher Risk for Surgery
Authors: K. Franks, L. Mcparland, J. Webster, D. Baldwin, D. Sebag-Montefiore, M. Evison, R. Booton, C. Faivre-Finn, B. Naidu, J. Ferguson, C. Peedell, M. Callister, M. Kennedy, W. Gregory, J. Hewison, J. Bestall, S. Bell, P. Hall, M. Snee
Journal: Journal of Thoracic Oncology (2018)
Influence of treatment with prior bevacizumab: A combined analysis of individual patient data from ASPECCT and WJOG6510G trial which compared panitumumab versus cetuximab in patients with wild-type KRAS exon 2 metastatic colorectal cancer
Authors: H. Taniguchi, T. Yamanaka, D. Sakai, K. Yamazaki, K. Muro, M. Peeters, T.J. Price
Journal: Annals of Oncology (2018)
Characterization of PD-L1, CD8, CD3, CD68 and PanCK in tumor microenvironment of Gl tract tumors with respect to patients’ mismatch repair status and anti-PD-1 treatment outcome using 5Plex IHC and whole slide image analysis
Authors: W. Zhang, M. Khojasteh, A. Hubbard, J. Martin, X. Wang, S. Kamthamraju, J.L. Munoz-Rodriguez, D. Jiang, Z. Cai, J. Li, R. Anders, L. Diaz, L. Pestic-Dragovich, L. Tang
Journal: Annals of Oncology (2018)
RORγ agonist LYC-55716 in combination with pembrolizumab to treat metastatic non-small cell lung cancer: An open-label, multicenter phase Ib trial
Authors: D.R. Camidge, S.M. Gadgeel, H.J. Wilkins, G. Weems, R. Santana-Davila, M. Johnson
Journal: Annals of Oncology (2018)
Randomised controlled trials in severe asthma: selection by phenotype or stereotype
Authors: Thomas Brown, Thomas Jones, Kerry Gove, Clair Barber, Scott Elliott, Anoop Chauhan, Peter Howarth
Journal: European Respiratory Journal (2018)

Previous publications have highlighted the disparity between research trial populations and those in clinical practice, but it has not been established how this relates to randomised controlled trials (RCTs) of phenotype-targeted biological therapies in severe asthma. Detailed characterisation data for 342 severe asthma patients within the Wessex Severe Asthma Cohort (WSAC) was compared against comprehensive trial eligibility criteria for published phase IIB and phase III RCTs evaluating biological therapies in severe asthma since 2000. 37 RCTs evaluating 20 biological therapies were identified. Only a median of 9.8% (range 3.5–17.5%) of severe asthma patients were found to be eligible for enrolment in the phase III trials. Stipulations for airflow obstruction, bronchodilator reversibility and smoking history excluded significant numbers of patients. A median of 78.9% (range 73.2–86.6%) of patients with severe eosinophilic asthma would have been excluded from participation in the phase III licensing trials of interleukin (IL)-5/IL-5R targeted therapies. Despite including only well characterised and optimally treated severe asthmatics under specialist care within the WSAC study, the vast majority were excluded from trial participation by criteria designed to re-confirm diagnostic labels rather than by biomarker criteria that predict the characteristic addressed by the treatment.
Somatostatin receptor 2 expression and clinical significance in pulmonary lymphoepithelioma-like carcinoma
Authors: S. Han, J. Yeong, C.X. Lim, M.-K. Ang, W.T.D. Lim, C.K. Toh, Q.S. Ng, D.S. Tan, T.K.H. Lim, J.H. Loh, A. Tanako, R. Kanesvaran, W.L. Tan, T. Rajasekaran, W. Nei, A. Jain
Journal: Annals of Oncology (2018)
OA10.04 Afatinib With or Without Cetuximab for EGFR-Mutant Non-Small Cell Lung Cancer: Safety and Efficacy Results from SWOG S1403
Authors: S. Goldberg, M. Redman, R. Lilenbaum, K. Politi, T. Stinchcombe, L. Horn, E. Chen, S. Mashru, S. Gettinger, M.A. Melnick, J. Miao, J. Moon, K. Kelly, D. Gandara
Journal: Journal of Thoracic Oncology (2018)
The impact of inclusion in home palliative program and distance to hospital on chemotherapy near end of life
Authors: J. Balsalobre, A. Checa-Soriano, P. Cerezuela-Fuentes, M. Martínez-Penella, M.J. Martínez-Ortíz, J.L. Alonso-Romero, M.I. Luengo-Alcázar, M.T. García-García
Journal: Annals of Oncology (2018)
LDR-Induced miR-30a and miR-30b Target the PAI-1 Pathway to Control Adverse Effects of NSCLC Radiotherapy
Authors: Gaeul Park, Beomseok Son, JiHoon Kang, Sungmin Lee, Jaewan Jeon, Joo-Hyung Kim, Gi-Ra Yi, HyeSook Youn, Changjong Moon, Seon Young Nam, BuHyun Youn
Journal: Molecular Therapy (2018)

Radiotherapy has been a central part in curing non-small cell lung cancer (NSCLC). However, it is possible that not all of the tumor cells are destroyed by radiation; therefore, it is important to effectively control residual tumor cells that could become aggressive and resistant to radiotherapy. In this study, we aimed to investigate the molecular mechanism of decreased NSCLC radioresistance by low-dose radiation (LDR) pretreatment. The results indicated that miR-30a and miR-30b, which effectively inhibited plasminogen activator inhibitor-1 (PAI-1), were overexpressed by treatment of LDR to NSCLC cells. Phosphorylation of Akt and ERK, the downstream survival signals of PAI-1, was decreased by PAI-1 inhibition. Reduced cell survival and epithelial-mesenchymal transition by PAI-1 inhibition were confirmed in NSCLC cells. Moreover, in vivo orthotopic xenograft mouse models with 7C1 nanoparticles to deliver miRNAs showed that tumor growth and aggressiveness were efficiently decreased by LDR treatment followed by radiotherapy. Taken together, the present study suggested that PAI-1, whose expression is regulated by LDR, was critical for controlling surviving tumor cells after radiotherapy.
Response to primary treatment for first recurrence independently influences survival of patients with hormone receptor-positive, HER2-negative breast cancer: A multicenter study of 236 recurrent metastatic patients
Authors: J. Yamamura, S. Kamigaki, M. Tsujie, J. Fujita, H. Osato, C. Higashi, H. Kanaizumi, Y. Tanaka, M. Hamada, W. Shinzaki, Y. Hasimoto, Y. Komoike
Journal: Annals of Oncology (2018)
Abstract 18079: Albuminuria in Adults With Congenital Heart Disease: Results From the Boston Adult Congenital Heart Biobank
Authors: Saurabh Rajpal, Laith Alshawabkeh, Justin Owumi, Robin Bradley, Elizabeth I Landzberg, Michael N Singh, Michelle Gurvitz, Finnian R McCausland, Sushrut S Waikar, Michael J Landzberg, Alexander R Opotowsky
Journal: Circulation (2016)

Introduction: Albuminuria is present in ~5-10% of the population with a higher prevalence among those with diabetes mellitus or hypertension. Its presence reflects microvascular dysfunction and is ...
OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC
Authors: J. Lin, D. Kim, A. Drilon, R. Doebele, J. Lee, V. Zhu, M. Ahn, J. Lim, S. Stopatschinskaja, J.J. Cui, D. Hyman, R. Camidge, S. Ou, A. Shaw, B.C. Cho
Journal: Journal of Thoracic Oncology (2018)
Jak2V617F and Dnmt3a loss cooperate to induce myelofibrosis through activated enhancer-driven inflammation
Authors: Sebastien Jacquelin, Jasmin Straube, Leanne Cooper, Therese Vu, Axia Song, Megan Bywater, Eva Baxter, Matthew Heidecker, Brad Wackrow, Amy Porter, Victoria Ling, Joanne Green, Rebecca Austin, Stephen Kazakoff, Nicola Waddell, Luke B. Hesson, John E. Pimanda, Frank Stegelmann, Lars Bullinger, Konstanze Döhner, Raajit K. Rampal, Dirk Heckl, Geoffrey R. Hill, Steven W. Lane
Journal: Blood (2018)
OA11.05 Phase II Study of Sunitinib in Patients with Thymic Carcinoma Previously Treated with Platinum-Based Chemotherapy (KOSMIC Trial)
Authors: S.H. Kim, Y.J. Kim, C. Ock, M. Kim, B. Keam, T.M. Kim, D. Kim, D.S. Heo, J.S. Lee
Journal: Journal of Thoracic Oncology (2018)
Impact of the 8th edition AJCC classification in early stage lung cancer
Authors: A.S. Cortegoso Mosquera, M. Vieito Villar, C. Rodriguez Lopez, V. Varela Pose, V. Cebey Lopez, J. Alvarez Fernandez, M. Perez Martelo, S. Aguin Losada, U. Anido Herranz, L. Leon Mateos, F.J. Baron Duarte, J.J. Garcia Gonzalez
Journal: Annals of Oncology (2018)
68Ga-PSMA-PET/CT imaging for locally advanced, recurrent and metastatic adenoid cystic carcinoma and salivary duct carcinoma
Authors: W. van Boxtel, S. Lütje, I. van Engen- van Grunsven, G. Verhaegh, J. Schalken, M. Janssen, J. Nagarajah, M. Gotthardt, C.M.L. van Herpen
Journal: Annals of Oncology (2018)
MA06.02 Prospective Immunogenomic Profiling of Non-Small Cell Lung Cancer: Genomic and Immune Profiling Updates from Project ICON
Authors: M. Negrao, A. Reuben, R. Chen, B. Sepesi, T. Karpinets, E. Parra, L. Federico, L. Vence, A. Weissferdt, H. Tran, A. Vaporciyan, C. Haymaker, M. Forget, M. Vasquez, E. Prado, C. Chow, J. Zhang, J. Fujimoto, J.A. Jack A. Roth, I.M. Meraz, E. Roarty, L.L. Landry, H. Wagner, E. Bogatenkova, C. Bernatchez, P.A. Futreal, I. Wistuba, S. Swisher, J. Heymach, D. Gibbons, J. Zhang
Journal: Journal of Thoracic Oncology (2018)
P2.03-26 A Prospective Cohort Study of TMB and Determinants of ctDNA Detection by Comprehensive Genomic Profiling in Stage I Lung Adenocarcinomas
Authors: K. Chen, H. Zhao, J. Bai, F. Yang, L. Chang, Y. Guan, X. Yi, L. Feng, S. Cheng, J. Wang
Journal: Journal of Thoracic Oncology (2018)